OR WAIT null SECS
October 05, 2026
Article
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
September 25, 2026
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
September 21, 2026
Video
Woolley discusses why an active placebo's own therapeutic effects complicate psilocybin trial blinding and outlines next steps for testing UMBRAA.
September 18, 2026
Josh Woolley, MD, PhD, says active placebos fail to mask high-dose psilocybin and propose combining drug classes with authorized incomplete disclosure.
September 17, 2026
In his paper, Josh D. Woolley, MD, PhD, proposes multidrug active placebos and limited disclosure to finally mask high-dose psilocybin trials.
September 01, 2026
A regulatory resubmission, 2 phase 3 psychedelic trial readouts, new TMS dosing data, and an MDD genetics study, all in this August 2026 recap.
August 10, 2026
Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.
April 23, 2026
Alva outlines how general clinicians should address patient questions on psychedelic therapies, including risks, approvals, and referral pathways.
April 22, 2026
Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.
April 20, 2026
Following an April 18 executive order, Gus Alva, MD, discusses psychedelic mechanisms, evidence, and clinical considerations for psychiatry.